JDRF Blog

Latest in Advocacy

  • FDA Approves Xeris Pharmaceuticals’ Glucagon to Treat Severe Hypoglycemia

    September 11, 2019

    “The approval of the GVOKE HypoPenTM is an important step forward for people with diabetes. Severe hypoglycemia is a terrifying and dangerous...

  • Testimony of Dr. Aaron Kowalski, Chief Mission Officer, JDRF House Energy & Commerce Committee Oversight And Investigations Subcommittee

    April 2, 2019

    ‘PRICED OUT OF A LIFESAVING DRUG: THE HUMAN IMPACT OF RISING INSULIN COSTS’ Chairwoman DeGette, Ranking Member Guthrie, Chairman Pallone, Ranking Member...

  • In a Step Backward, UnitedHealthcare Changes Policy to Limit Insulin Pumps for Children

    February 4, 2019

    On February 1, 2019, UnitedHealthcare (UHC) announced a significant change to its insulin pump coverage policy, as it will no longer cover...

  • Congress, Protect Coverage for Pre-Existing Conditions for People with T1D

    December 15, 2018

    In the past year, tens of thousands of JDRF advocates have supported the #Coverage2Control campaign and our push for affordability, choice and...

  • Recognize. Recharge. Repeat. Appreciating Our Shared Success.

    July 30, 2018

    Whenever the JDRF community gathers, one thing remains clear: our singular focus on the fight to end type 1 diabetes (T1D) has...

  • JDRF Honors Community Volunteers at 2018 One Conference

    July 11, 2018

    On Wednesday, July 11, chapter volunteers and members of the JDRF staff gathered together for the annual One Conference in Washington, D.C....

  • JDRF Top Advances Over the Past Year

    July 5, 2018

    At JDRF, we are committed to funding the development of new therapies to keep people with type 1 diabetes (T1D) healthier, longer,...

  • JDRF Goals Supported in FDA Approvals of New T1D Technology

    June 25, 2018

    JDRF has always had an ambitious advocacy agenda to support continued Federal research funding, ensure regulatory frameworks that encourage innovation and promote...